Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL19359143 | 1.00 | PTGS1 (0.52) | PTGS1SLC7A11ALPIPKMXIAP | |
| Cysteine SCHEMBL1889352 | 0.79 | PTGS1 (0.46) | PTGS1SLC7A11IDO1TDO2GRIA1 | |
| Cysteine SCHEMBL16208953 | 0.78 | PTGS1 (0.61) | PTGS1SLC7A11ALPIPKMXIAP | |
| Cysteine SCHEMBL27864571 | 0.78 | PTGS1 (0.61) | PTGS1SLC7A11ALPIPKMXIAP | |
| Cysteine SCHEMBL987552 | 0.78 | PTGS1 (0.61) | PTGS1SLC7A11ALPIPKMXIAP | |
| Cysteine SCHEMBL28009382 | 0.76 | PTGS1 (0.89) | PTGS1SLC7A11ALPIPKMXIAP | |
| Phthalimide SCHEMBL4392749 | 0.75 | PTGS1 (0.53) | PTGS1SLC7A11ALPIPKMXIAP | |
| SCHEMBL1826601 | 0.73 | PTGS1 (0.36) | PTGS1SLC7A11 | |
| Hydrogen Sulfide SCHEMBL2431729 | 0.72 | GSK3B (0.32) | — | |
| Cysteine SCHEMBL95110 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752215-B2 | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210299270-A1 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-09-30 | — | — | US | disclosed |
| US-20190151464-A1 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES | UNIV RUTGERS (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3429586-A1 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES | Rutgers, the State University of New Jersey (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017161288-A1 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-09-21 | — | — | WO | disclosed |